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Antimicrobial peptides (AMPs) are a heterogeneous class of compounds found in a variety of organisms including humans and,
so far, hundreds of these structures have been isolated and characterised. They can be described as natural microbicide, selectively
cytotoxic to bacteria, whilst showing minimal cytotoxicity towards the mammalian cells of the host organism. They act by their
relatively strong electrostatic attraction to the negatively charged bacterial cells and a relatively weak interaction to the eukaryote
host cells. The ability of these peptides to accumulate at sites of infection combined with the minimal host’s cytotoxicity motivated
for this review to highlight the role and the usefulness of AMPs for PET with emphasis on their mechanism of action and the
different interactions with the bacterial cell. These details are key information for their selective properties. We also describe the
strategy, design, and utilization of these peptides as potential radiopharmaceuticals as their combination with nuclear medicine
modalities such as SPECT or PET would allow noninvasive whole-body examination for detection of occult infection causing, for
example, fever of unknown origin.
1. Introduction
Compared with other conventional technologies, tomo-
graphic imaging can evaluate disease processes deep within
the body, noninvasively and relatively rapidly. It is therefore
not surprising that molecular imaging has powerfully aug-
mented the investigation of various disease processes and has
become an essential tool in the field of oncology, for both
research and patient care [1]. Another major advantage of
imaging is its ability to provide a holistic, three-dimensional
assessment of the whole organ or body, less likely to be
limited by sampling errors and therefore corelating well with
the overall disease process. While continued advances in
molecular imaging have provided unparalleled opportunities
for more refined methods to monitor diseases, tools for
evaluating infection and inflammation remain limited. Two
imagingmethods, widely used in the clinics currently, include
high resolution computed tomography (CT) that measures
anatomic (and therefore late) changes or 18F-labeled 2-fluoro-
deoxy-D-glucose (18F-FDG)-positron emission tomography
(PET), which is a general marker of metabolic activity.
As 18F-FDG is also accumulating in sites of infection and
inflammation due to the elevated glucose metabolism in
these loci [2], thus it is nonspecific for infection. Therefore it
became increasingly important to develop more specific and
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selective infection imaging agents. Direct, ex vivo, labeling
of leukocytes is considered the “gold standard” for infection
imaging by PET. Unfortunately this process is very laborious
and time-consuming and requires the handling of blood
products [3–5]. Alternatively, indirectly labeled leukocytes
can be achieved using radiolabeled molecules, such as
chemotactic peptides or cytokines, that bind to receptors
on the leukocytes [3]. Unfortunately the biological effects
of some of the leukocyte receptor-targeting compounds
have limited their clinical use as infection-specific molecular
imaging agents [5]. Although the most commonly labeled
leukocytes, neutrophils and lymphocytes, are quite selective
for infection, there are cases when they may fail to detect an
infection or accumulate in noninfected sites. If the infection
fails to elicit an immune response, labeled leukocytes will not
accumulate at the infected loci, which may be the case in
a severely immune-compromised individual, or in the case
of infection by certain pathogens, such as Mycobacterium
tuberculosis or Pneumocystis carinii. Some noninfectious
immune conditions, such as rheumatoid arthritis, may also
provoke an immune response and accumulate the tracer
[3]. Through the use of different tracers, different targeting
strategies are possible to image infection using PET.
Tracers that interact directly with the pathogenic
microbes responsible for infection are, by nature, highly
specific for infection and unlike labeled leukocytes should not
accumulate in sterile inflammations. These types of tracers
include radiolabeled antibiotics and antimicrobial peptides.
Technetium-99m labeled ciprofloxacin (99mTc-ciprofloxacin)
has been the most widely studied antibiotic-based tracer
for SPECT infection imaging [6] targeting DNA Gyrase, an
enzyme present in all dividing bacteria and is not thought
to accumulate in dead bacteria or sterile inflammations.
Some problems associated with its use as a tracer in SPECT
infection imaging have occurred with regards to poor
radiochemical purity and stability [3]. More recently it has
been reported that localisation at infected foci takes place
primarily through increased extravasation and stasis. This
process also occurs at uninfected sites with increased vascular
permeability and 99mTc-ciprofloxacin may accumulate at
sites of sterile inflammation thereby reducing its specificity
for infection [7].
Antimicrobial peptides (AMP) have attracted interest as
potential targeting vectors for the development of PET tracers
designed for the detection of infection. These peptides are
found in a variety of organisms including humans, and,
so far, hundreds have been isolated and characterised. It
is believed that these peptides function as broad-spectrum
microbicides and form part of the innate immune system
of many eukaryotes, including humans. Regardless of their
origin, they share many common properties such as having
a net positive charge, being amphipathic and, in most cases,
are membrane active [8]. Due to their role in the body
as a natural microbicide, these antimicrobial peptides are
selectively cytotoxic to bacteria, whilst showing minimal
cytotoxicity towards cells of the host organism. It is thought
that the net cationic nature of the peptides results in a
relatively strong electrostatic attraction to negatively charged
bacterial cells and a relativelyweak attraction to the eukaryote
host cells, which are usually less negatively charged than
prokaryotes, and is believed to form the basis of this cell-type
discrimination [9].The ability of these peptides to accumulate
at sites of infection combined with their almost negligible
cytotoxicity or attraction to host cells makes these peptides
attractive as targeting vectors for PET imaging of infection
[10].
2. Overview of Antimicrobial Peptides
Antimicrobial peptides are evolutionarily conserved biom-
olecules that form part of the defence mechanisms in many
organisms [11], ranging from prokaryotes to multicellular
animals such as humans [9]. They form part of the first line
of defence against pathogenic microbes in higher animals
and in many lower forms of life; they are the only form of
defence against pathogenic and saprophytic microbes [12].
The selective cytotoxicity of these peptides, where they attack
the pathogenic microbes and leave the host cells unharmed,
is due to the fundamental differences in composition and
structure of the host cells to those of the pathogenic bacteria
and yeasts. Despite some AMPs showing immunomodula-
tory effects and/or chemotactic behaviour, a common feature
of these antimicrobial peptides is that they are amphipathic
but possess an overall positive charge [9]. Approximately
1500 antimicrobial peptides have been characterised in awide
range of organisms and classification of these peptides can
be complicated due to the high degree of sequence dissim-
ilarity between the various peptides. However, classification
has been attempted based on amino acid composition and
secondary structures.
Three large groups (Table 1) have been identified, namely,
𝛼-helical peptides, cysteine-containing 𝛽-sheet peptides, and
flexible peptides rich in specific amino acids such as proline,
tryptophan, histidine, arginine, and glycine [13].
2.1. 𝛼-Helical Antimicrobial Peptides. Approximately 30 to
50% of all antimicrobial peptides identified and studied to
date contain predominant 𝛼-helical structures. This may
be due the relative ease with which these peptides are
chemically synthesised, which allows for extensive charac-
terisation in the laboratory. These peptides usually consist
of 12–40 amino acid residues and contain an abundance of
helix stabilising residues such as alanine, leucine, and lysine
but never cysteine. In aqueous solutions these peptides are
often unstructured but assume their amphipathic 𝛼-helical
conformations when associated with a cell membrane or in
a membrane mimetic environment. Often these peptides are
not strictly 𝛼-helices and may contain an internal kink [14].
2.2. 𝛽-Sheet Antimicrobial Peptides. Theothermajor group of
antimicrobial peptides are those that typically contain two to
ten cysteine residues that form one to five interchain disulfide
bonds. This bonding interaction allows these peptides to
adopt the 𝛽-sheet conformation. Most 𝛽-sheet antimicrobial
peptides are part of the defensin family and these peptides
are evolutionarily conserved across plants, fungi, insects,
molluscs, and vertebrate animals. Defensins typically consist
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Table 1: Representative antimicrobial peptides of different classifi-
cations (modified from [13]).
Class Representatives Host
𝛼-helical
LL-37 Mammal: human
Cecropins Insect: moth
Melittin Insect: honey bee
Magainins Amphibian: frog
Fowlicidins Ave: chicken
𝛽-sheet
Thanatin Insect: soldier bug
Tachyplesins Arthropod: horseshoe crab
Protegrins Mammal: pig
Plant defensin VrD2 Plant: mung bean
Plectasin Fungus: ebony cup
Insect defensin A Insect: northern blow fly
𝛼-defensin Mammal: human
𝛽-defensin Mammal: human
𝜃-defensin Mammal: rhesus monkey
Flexible
Indolicidin Mammal: cow
Tritrpticin Mammal: pig
Histatins Mammal: human
PR-39 Mammal: pig
of two to three antiparallel 𝛽-sheets stabilized by three to
four intramolecular disulfide bonds; however in some cases
an 𝛼-helical or unstructured segment is found at the N-
or C-terminus. Unlike the 𝛼-helical antimicrobial peptides,
which are unstructured in aqueous solutions, the defensins
maintain a compact globular structure under such condi-
tions [12, 13]. Apart from overall similarity in secondary
structure, most mammalian-derived 𝛼-defensins possess two
additional common features, namely, a protruding loop
resulting from a conserved arginine/glutamate salt bridge
and a 𝛽-bulge caused by a conserved glycine-X-cysteine (X:
any amino acid) motif between the first and second cysteine
residues [13].
2.3. Flexible Antimicrobial Peptides Rich in Specific Amino
Acids. A minority of antimicrobial peptides contain a high
proportion of certain amino acids such as proline, trypto-
phan, histidine, arginine, and glycine. Representative mem-
bers of this class include the tryptophan rich bovine indoli-
cidin and porcine tritrpticin, histidine rich human histatins,
and the arginine and proline-rich porcine PR-39. Due to
their unusual amino acid compositions, these peptides have
highly variable secondary structures. The 13-amino acid
indolicidin (ILPWKWPWWPWRR), for example, adopts a
largely extended conformation in the presence of zwitte-
rionic micelles composed of substances such as dodecyl-
phosphocholine or anionic sodium-dodecyl sulfate [13].
3. Mechanisms of Cell Specificity and
Selectivity of Antimicrobial Peptides
Inherent differences in the microbial versus the host cell
membrane composition and architecture aid selectivity of the
antimicrobial peptides. Regulation of expression or locali-
sation of the peptides is also thought to prevent unwanted
interactions with vulnerable host cells.
3.1. Target Specificity and Selective Cell Toxicity. A biological
membrane can be thought of as simply a fluid mosaic
consisting of phospholipids interspersed with proteins. In
different organisms glycerides and sterolsmay also contribute
to the biochemical architecture and surface topology of such
membranes.There are, however, fundamental differences that
exist between microbial and animal cell membranes that
allow the antimicrobial peptides to distinguish between these
cells and selectively target one over the other as sketched in
Figure 1 [9].
3.2. Membrane Composition, Charge, and Hydrophobicity.
The core component of almost all natural biomembranes
is the phospholipid bilayer. These bilayers are amphipathic,
meaning they have both hydrophobic and hydrophilic
regions. However, eukaryotic and prokaryotic cell mem-
branes differ significantly in terms of exact composition
and cell energetics (Figure 2). Phosphatidylcholine (PC) and
its analogue sphingomyelin (SM) as well as phosphatid-
ylethanolamine (PE) have no charge under physiological con-
ditions [9]. Cholesterol and other sterols such as ergosterol
which are abundantly found in eukaryotic membranes, but
very seldom in prokaryotic membranes, are also generally
neutrally charged (Figure 2) [15]. Hydroxylated phospho-
lipids such as phosphatidylglycerol (PG), cardiolipin (CL),
and phosphatidylserine (PS) possess a net negative charge
under physiological conditions. It can be seen how the charge
of the membrane is mainly due to the ratio and location of
the various phospholipids, with cell membranes comprising
mostly PG, CL, and PS, as is the case in most pathogenic bac-
teria, being very electronegative, whereas those membranes
that are rich in PC, PE, or SP tend to have a net neutral charge,
as is the case in mammalian cell membranes [15, 16].
3.3. Membrane Asymmetry. Although cellular membranes
are neither symmetric nor static, differences between mam-
malian and microbial phospholipid bilayers can serve as
potential targets for antimicrobial peptides. In some cells
such as the bovine erythrocyte, only 2% of the total PE con-
tent is located on the outer membrane leaflet [13]. Differences
in membrane symmetry, saturation of phospholipid bilayers,
and compositional stoichiometry will influence the mem-
brane’s fluidity and phase transition. In a similar manner, the
charge of the inner and outer leaflets of the cellular bilayer
may also be different [15].
3.4. Microbial Ligands and Receptors as Targets for Antimi-
crobial Peptides. Experiments have shown that D-and L-
amino acid versions of antimicrobial peptides exhibit similar
binding affinities to targets cells, suggesting that stereospe-
cific receptors are not involved in targeting pathogenic
cells [9]. However, several studies appear to refute this and
suggest that certain proteins located in the microbial cell
membrane may serve as binding targets for certain classes of
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Figure 1: Membrane targeting of antimicrobial peptides and basis of their selectivity (adapted from [45]).
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Figure 2: Comparative lipid architecture of microbial and human
cytoplasmic membranes. Cytoplasmic membranes of bacterial
(Escherichia coli, Staphylococcus aureus, or Bacillus subtilis) and
fungal (Candida albicans) pathogens are compared with that of
the human erythrocyte in relative composition and distribution
between inner and outermembrane leaflets.Membrane constituents
ranging from anionic (left) to neutral (right) are CL, PG, PE, PC,
SM, and sterols (cholesterol or ergosterol, ST). Note the marked
difference among microbial pathogens and human erythrocytes
resides in the phospholipid composition and asymmetry. These
differences are believed to account for the selective antimicrobial
peptide affinity for microbial versus host cells to the extent that
it exists for a given antimicrobial peptide. Keys: open, E. coli;
horizontal hatching, S. aureus; shaded, B. subtilis; checkered, C.
albicans; solid, human erythrocyte (adapted from [9]).
antimicrobial peptides such as histatins. This would support
the findings why histadins are involved in local defence
mechanisms with particular type of pathogens and have been
recovered in dental or skin wounds. Some researchers also
postulate that anionic components of cell membranes, for
example, CL, PG, or lipopolysaccharide (LPS), may serve
as pseudoreceptors, enabling the initial interaction between
the antimicrobial peptide and the microbial cell target [13].
Hence, antimicrobial-binding receptorsmay be an alternative
pathway of AMP interaction with the bacterial cell envelop.
3.5. Transmembrane Potential. The transmembrane potential
is yet another way in which microbial and mammalian cells
vary and it is in the charge separation that exists between
the inner and outer layers of the cytoplasmic membrane. An
electrochemical gradient, resulting from the differing rates
or proton exchange across the cell membrane, is referred to
as the transmembrane potential (Δ𝜓). A normal mammalian
cell has a Δ𝜓 between −90 and −110mV in range. Pathogenic
bacteria, however, generally exhibit Δ𝜓 in the −130 to
−150mV range.This significant difference in electrochemical
potential may be another factor that allows antimicrobial
peptides to distinguish between host and target cells [9].
4. Selective Toxicity Based on
Antimicrobial Peptide Design
In the aqueous intercellular environment, many antimicro-
bial peptides are believed to adopt extended or unstructured
conformations, although this may not be the case if there are
intramolecular bonds present, which will ensure a specific
conformation in a variety of environments due to induced
rigidity. Once the antimicrobial peptide binds to the cell
membrane of a pathogenic microbe, it may undergo signif-
icant conformational change and adopt a specific conforma-
tion, such as a 𝛼-helix. Studies suggest that dynamic and/or
inherent conformations of antimicrobial peptides have an
effect on their selective cytotoxicity [9, 17, 18]. Additionally,
antimicrobial peptides may undergo conformational tran-
sition, self-association, or oligomerization within the target
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pathogen membrane, but not the host cell membrane to
increase cell-specific toxicity [13]. Zhang and coworkers [16]
employed synthetic test peptides that were uniformly cationic
but varied in conformation and included extended, cyclic,
𝛼-helical, and 𝛽-sheet structures. It was determined that
all test peptides were able to interact with and penetrate
lipid monolayers composed of PG, a negatively charged
phospholipid. However, only the 𝛼-helical and extended
peptides were able to interact with themore neutrally charged
PC membrane. In the same study it was also found that 𝛽-
sheet peptides were able to translocate phospholipids from
the inner to the outer leaflet at concentrations that were lower
than those that were required to permeabilize the membrane.
Similarly, Kol and coworkers [19] showed that peptides with
comparable conformation, but rich in histidine and lysine
and lacking in tryptophan, were also able to induce significant
levels of phospholipid translocation. It can be concluded from
these studies that not only do antimicrobial peptides interact
with phospholipid membranes of only specific composition
and symmetry, but they are also able to affect remodelling of
the membranes in specific cells.
4.1. In Vivo Preferential Affinity for Microbial versus Mam-
malian Cells. Welling and colleagues [20] conducted an in
vivo experiment where they tested the binding affinity of a
radiolabeled fragment of the cationic ubiquicidin antimicro-
bial peptide 99mTc-UBI 29–41 for microbial cells as compared
to host cells. In the study, animals were infected withCandida
albicans, Klebsiella pneumonia, or Staphylococcus aureus.
Sterile inflammations were also induced in the thigh muscles
of animals through injection of heat-killed microorganisms
or purified LPS, to serve as controls. The radiolabeled pep-
tides accumulated to a significant extent in the infected sites
relative to sterile or noninfectiously inflamed parts of the
body.This in vivo experiment demonstrated that the peptides
could distinguish between host and microbial cells and also
accumulate at the infected sites. Through scintigraphic mea-
surements it was determined that the radiolabeled peptides
accumulated in infected tissues at a rapid rate and that there
was up to a fivefold increase in rates of accumulation in
infected tissues relative to noninfected tissues. This rapid
localizationwas interpreted as the peptides having a higher or
preferential affinity for the target cell surface relative to that
of the host cell surface.
4.2. Localisation of Cytotoxic Antimicrobial Peptides Limits
Exposure of Vulnerable Host Tissues. It is possible that host
cell cytotoxicity is reduced in many multicellular organisms
due to their localization to tissues that are not vulnerable
to their cytotoxic effects. In most animals these peptides are
secreted by cells onto relatively inert and robust surfaces such
as the epithelia of the intestines or lung, or in amphibians,
onto the skin. These localities are most likely to interact
with potentially harmful microbes most frequently, and the
expression of most of the antimicrobial peptides is either
constitutive or rapidly inducible, to allow them to form part
of the first defences against pathogens [9]. Another means of
protecting sensitive host tissues from antimicrobial peptides
is by containing them within granules in the phagocyting
leukocytes, which engulf pathogens and expose them to
lethal concentrations of antimicrobial peptides and oxidiz-
ing agents. The defensin class of antimicrobial peptides is
deployed in thisway, since they are someof themost toxic and
least selective of the host produced antimicrobial peptides.
The slightly acidic microenvironment within the mature
phagolysosome is also the most effective environment for the
defensins, as they exhibit maximum cytotoxicity under these
conditions [12].
5. Mechanisms of Antimicrobial
Peptide Action
The generally conserved structures of antimicrobial peptides,
across a wide variety of organisms, lend some clues as to their
mechanisms of action. They are almost exclusively amphi-
pathic and cationic under physiological conditions, and this is
believed to aid their target cell selectivity.The ideal antimicro-
bial peptide should have low host cell cytotoxicity but be toxic
to a wide range of pathogenic microbes. The antimicrobial
determinants should be easily accessible and should not be
prone to change or alteration. In general, antimicrobial pep-
tides have amphipathic structures that allow them to interact
with phospholipid membranes, structures that are essential
to all pathogens [17]. Parameters such as conformation (𝑋),
hydrophobicity (𝐻), hydrophobicmoment (𝑀
𝐻
), charge (𝑄),
polar angle (𝜃), and amphipathicity (𝐴) are all important
to the functioning of antimicrobial peptides. Furthermore,
all these determinants are interrelated and modification of
one of these features will lead to alteration of the others
[9].
5.1. Conformation (𝑋). Although antimicrobial peptidesmay
be found in a wide range of host organisms and have differing
amino acid sequences, they can be classified into a few
discrete groups based on their secondary structure. The two
largest groups include peptides that possess a 𝛽-sheet or 𝛼-
helical secondary structure. The majority of the remaining
antimicrobial peptides are those that have an unusually high
proportion of one or more amino acids such as tryptophan
or proline and arginine.The 𝛼-helical peptides are frequently
found in the intercellular fluid of insects and amphibians and
generally adopt an unstructured or extended conformation in
aqueous solution, only adopting their helical structure upon
interaction with a phospholipid membrane [21]. The reason
for this is that the intramolecular hydrogen bonding required
for an 𝛼-helic conformation is disrupted in a polar solvent
such as water. In a membrane, the polar hydrogen bonding
groups are shielded from lipophilic (apolar) membrane envi-
ronment through 𝛼-helic formation. The helix conformation
also exposes the apolar side chains to the neutral lipid
environment inside the membrane. Although the primary
structure of the 𝛽-sheet class of antimicrobial peptides shows
a level of dissimilarity in amino acid sequence, they all
share common features with regard to amphipathic structure,
possessing distinct hydrophilic and hydrophobic domains
[9].
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5.2. Charge (𝑄). Most of the antimicrobial peptides are
overall cationic and have charges ranging from +2 to +9, with
many possessing highly defined negatively charged domains.
This positive charge is important for the initial attraction
to and interaction with the anionic cellular membranes of
bacteria and other pathogenic microorganisms. Likewise
the relatively less anionic membranes of the host do not
electrostatically attract the antimicrobial peptides and may
confer some target cell selectivity to the peptides. Pathogenic
bacteria are generally rich in acidic phospholipids such as
CL, PG, and PS. Additionally the teichoic and teichuronic
acids of the cell walls of Gram-positive bacteria and the LPS
of Gram-negative bacteria confer additional electronegative
charge to the bacterial cell surface. It has been determined
that the Δ𝜓 of bacteria is typically 50% higher than that of
mammalian cells and it has been proposed that antimicrobial
peptides may be concentrated onto the surface of pathogenic
microbes in an electrophoretic manner [22]. Although many
studies were able to correlate the cationicity of antimicrobial
peptides with their antimicrobial activity, a strictly linear
relationship does not exist. Dathe and coworkers [23] demon-
strated in studies with analogues of magainin that increasing
the cationicity from +3 to +5 resulted in an increase in
antibacterial activity against both Gram-positive and Gram-
negative species. They did, however, note that there was
a limit to cationicity, after which any increases in positive
charge no longer increase antibacterial activity. It is believed
that this decrease in antibacterial activity may have been due
to the peptides binding so strongly to the negatively charged
phospholipid head group that translocation of the peptide
into the cell was impossible [9].
5.3. Amphipathicity (𝐴) and Hydrophobic Moment (𝑀
𝐻
).
Amphipathicity is a nearly universal feature amongst antimi-
crobial peptides and is achieved through a number of dif-
ferent peptide structures. The amphipathic 𝛼-helix is one
of the most common and simplest of these features. By
alternating anionic and cationic amino acid residues at every
three to four positions the peptide is able to adopt a secondary
structure that allows for optimal electrostatic interaction
with amphipathic phospholipid membranes (Figure 3). This
feature allows the peptide to exert cytotoxic activity towards
not only negatively charged cell membranes but also those
with a neutral charge or amphipathic nature [14].
Amphipathicity of a peptide can be described by its
hydrophobic moment (𝑀
𝐻
) which can be calculated as the
vectorial sum of individual amino acid hydrophobicities,
normalized to an ideal helix. An increase in hydrophobic
moment correlates to increased permeabilization of the target
cell membrane. This is especially significant in interactions
with lipid membranes that are neutrally charged, where
charge factors are unlikely to bring about the required
attraction to and interaction with the target cell membrane
[17]. Like the 𝛼-helical antimicrobial peptides, the 𝛽-sheet
host defence peptides also exhibit amphipathicity. This is
manifested as varying numbers of 𝛽-strands organised to
form hydrophobic and hydrophilic surfaces. The 𝛽-strands,
which are often antiparallel, are stabilised by regularly spaced
disulphide bonds or by cyclisation of the peptide backbone.
This intramolecular bonding allows 𝛽-sheet antimicrobial
peptides to maintain a rigid conformation even in aqueous
extracellular fluid and also facilitates multimerization, as the
hydrophobic surfaces will cluster together to avoid exposure
to the aqueous environment. Although the exactmechanisms
by which amphipathic antimicrobial peptides bring about
membrane disruption in the target cell membrane is unde-
termined at present, largely because the exact conformation
of the peptides in the membranes is not known, studies
have shown that segregated amphipathicity in both 𝛼-helical
and 𝛽-sheet antimicrobial peptides has a profound effect on
peptide disruption of natural biomembranes [9].
5.4. Hydrophobicity (𝐻). The hydrophobicity of a peptide
may be defined as the percentage of hydrophobic amino
acid residues making up its primary structure. For most
antimicrobial peptides the hydrophobicity is around 50% and
is essential for the functioning of the peptide as it allows
the peptide to interact with and penetrate into the phos-
pholipid bilayer. Although a certain amount of hydropho-
bicity is essential for the functioning of the antimicrobial
peptide, excessive hydrophobicity will increase its likelihood
of destroying the host’s cells and reduce its specificity for
microbial cells [24]. Wieprecht and coworkers [25] studied
the relationship between the hydrophobicity of peptides and
their ability to permeabilize biomembranes. Using maga-
inin analogues as model antimicrobial peptides, they were
able to keep factors such as hydrophobic moment, helicity,
and charge nearly constant, whilst producing analogues
of variable hydrophobicity. Their experiments showed that
hydrophobicity had little or no effect on the peptide’s ability
to bind to or permeabilize the membrane when it consisted
exclusively of PG. However, inmembranes consisting of a 3 : 1
ratio of PC : PG, the peptides with the highest hydrophobicity
had an approximately 60-fold higher permeabilizing ability
than the least hydrophobic peptide, and in membranes
composed of only PC there was a 300-fold difference.
5.5. Polar Angle (𝜃). A peptide’s polar angle refers to the
relative proportion of polar to nonpolar facets of the peptide
conformed to an amphipathic helix. A helical peptide with
one facet composed entirely of polar amino acid residues
and the other facet composed entirely of nonpolar residues
would have a polar angle of 180∘. Less segregation between
the domains, or an overabundance of hydrophobic residues,
would lead to a lower polar angle. Studies conducted by
Uematsu andMatsuzaki [26] on both synthetic and naturally
occurring peptides have shown that a lower polar angle
and therefore a more hydrophobic facet is more conducive
to membrane permeabilization. Polar angle has also been
correlated with the stability of peptide induced pores in
biomembranes. They also demonstrated that antimicrobial
peptides with smaller polar angles were able to induce higher
degrees of membrane permeabilization and translocation at
higher rates than peptideswith greater polar angles. However,
the pores formed by the peptides with smaller polar angles
were less stable than those formed by peptides with greater
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Figure 3: Statistical analysis of residue distribution in the 20-residue N-terminal stretch 𝛼-helical AMPs from natural sources. A graphical
representation of the frequency of different types of residue at each position on a helical wheel projection is shown. The uneven distribution
of hydrophobic and charged peptides contributes to the amphipathic nature of the peptide (adapted from Tossi et al. [17]).
polar angles. Hydrophobic and hydrophilic properties of
antimicrobial peptides can be seen to play vital roles in the
interactions with and permeabilization of phospholipid cell
membranes [18].
5.6. Common Structural Features of Antimicrobial Peptides.
Whilst a wide variety of antimicrobial peptides do exist in
nature, conservation of key features and secondary structures
has been noted. Extremes of features such as amphipathicity,
charge, hydrophobic moment, or polar angle are not benefi-
cial since they tend to compromise either antimicrobial activ-
ity or lead to increased host cell cytotoxicity. The minimum
charge that peptides may possess in order to exert any kind
of antimicrobial activity appears to be +2. This minimum
cationicity is important because it allows for the initial
electrostatic attraction to the bacterial membrane, which is
negatively charged. It also allows for the displacement of
any other cations that may already be bound to the target
cell membrane and for the translocation into the interior
of the membrane bilayer. Similarly, the hydrophobicity of
the peptide should be moderate, since very hydrophobic
antimicrobial peptides would target membranes with a net-
neutral charge, such as the host cells, leading to a reduction
in target selectivity and damage to the host organism. It
can be seen that selective targeting of pathogenic microbes
is largely due to a balance between electronegativity and
hydrophobicity of the antimicrobial peptides [9].
6. Initial Interactions with the Targeted
Cellular Membrane
The initial interaction between the antimicrobial peptide
and the cell’s phospholipid membrane is important as it
determines target cell selectivity and also influences any
subsequent interactions with the target cell. The initial
interactions are largely determined by physical and chemical
features of both the antimicrobial peptide and the target cell
membrane [12].
6.1. Electrostatic Interactions. Electrostatic interactions are
widely believed to be responsible for the initial targeting
of the microbial cell. A study by Matsuzaki [27] correlated
antimicrobial peptide cationicity with membrane binding
ability, and the fact that cationicity is a conserved feature of
almost all antimicrobial peptides in awide range of organisms
further supports this argument. Electrostatic forces act over
a long range and the abundance of lysine and arginine
residues in antimicrobial peptides, which are attracted to
the negatively charged phosphate groups of biomembranes,
lends further credibility to the theory that these interactions
are responsible for the initial attraction to the target cell
membrane [12]. In Gram-negative bacteria it is believed that
the antimicrobial peptides displace cations that are normally
associated with the LPS, since antimicrobial peptides possess
a binding affinity for the LPS that is approximately three
orders of magnitude greater than the divalent cations usually
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associated with this moiety. Strains of bacteria where the LPS
is highly substituted with 4-amino-4-deoxy-L-arabinose or is
highly acylated show greater resistance to positively charged
antimicrobial peptides, lending further credibility to the
theory that electrostatic charge is important for interaction
with the target cell membrane [28]. Gram-positive bacteria
lack an LPS or outer cell membrane, but they do have
a thick cell wall made up of teichuronic or teichoic acid
polymers.These highly anionic structures are ideal targets for
the cationic antimicrobial peptides. Strains of Staphylococcus
aureuswhere the teichoic acids have beenmodified, resulting
in increased anionic charge, are more susceptible to cationic
antimicrobial peptides [29–31]. The fact that most bacteria
have a strong electrochemical gradient (Δ𝜓) relative to
mammalian cells is also thought to increase target selectivity
of antimicrobial peptides [9].
6.2. Receptor-Ligand Interactions with the Membrane. Some
studies have shown that both naturally occurring and syn-
thetic peptides interact with the membrane equally well
regardless of whetherD-amino or L-amino acids are used [32,
33]. This would suggest that interactions with biomembranes
are not dependant on receptor-ligand mechanisms; however,
other studies have shown that this may not be the case with
all antimicrobial peptides. Nisin, a naturally occurring, cyclic
peptide with powerful antimicrobial action has been found
to bind specifically to bacterial membrane bound lipid II
[34, 35]. Similarly, tachyplesin has been shown to have a
specific affinity for LPS. The data from these studies suggests
that receptor mediated binding is important for cell targeting
in a small number of antimicrobial peptides [34].
7. Events following Initial Membrane Binding
Experimental determination of initial attraction of peptides
to and interaction with cellular membranes is usually sim-
pler than determination of interactions that follow this. A
variety of methodologies such as circular dichroism [22,
36], X-ray crystallography, nuclear magnetic resonance [37],
reverse phase-high performance liquid chromatography, and
surface plasmon resonance [22], amongst other techniques,
have been used to elucidate peptide-membrane interactions.
However, it is suggested that the antimicrobial efficacy and
mechanisms are extremely sensitive to conditions such as
pH, osmotic strength, solution viscosity, and temperature, so
any data obtained by the above mentioned techniques must
be viewed with regard to these conditions [9]. Subsequent
to the initial membrane binding, antimicrobial peptides
penetrate the outer phospholipidmembrane, a phase referred
to as threshold concentration, and in doing so is able to
exert their cytotoxic effects in the interior of the cell. The
entry into the cell by the peptides requires a minimum
number, or threshold concentration of antimicrobial peptides
to accumulate on the surface of the lipid membrane. This
event can be affected by factors other than concentration
such as the ability of the peptides to multimerize and
also features of the phospholipid membrane itself, such as
its lipid composition, head group size, and fluidity [38].
The transmembrane potential of the bilayer may also influ-
ence theway inwhich the peptide enters themembrane, since
a highly negative transmembrane potential will facilitate pore
formation by drawing the positively charged peptide into the
membrane [39].
8. Changes in Peptide Conformation upon
Interaction with the Membrane
Many antimicrobial peptides, especially those with 𝛼-helical
secondary structures undergo significant conformational
rearrangement upon entering the nonpolar environment of
the inner membrane. The 𝛼-helical antimicrobial peptides
are normally disordered in the extracellular environment,
exhibiting random coil or extended structures, but rapidly
conform to a structured 𝛼-helix when associated with the
biomembrane [18]. Some antimicrobial peptides can only
undergo this conformational change in association with a
negatively charged bilayer membrane. This may be due to
the way the lipids are arranged in such membranes, with
the phospholipid head groups inducing optimum periodicity
of the cationic amino acid residues in the peptide, which
in turn promotes correct conformation into the helical
secondary structure [40, 41]. It has been suggested that this
feature ensures that the antimicrobial peptides will only
be “activated” into the cytotoxic form in the presence of
the target cell membrane, in this case a negatively charged
bacterium, and will not indiscriminately damage nontarget
host cells [17]. The intramolecular disulphide bonds found in
𝛽-sheet peptides ensure that they maintain their secondary
structure even in aqueous environments, and so they do not
undergo the drastic conformational rearrangements seen in
𝛼-helical peptides, although quaternary peptide structures
may disassociate upon entering the membrane, and this
could facilitate selective toxicity [9]. Following the initial
interaction with the cell membrane, many peptides may
undergo self-association which, when combined with lipid-
peptide interactions, may lead to the creation of complex
structures that contribute to the cytotoxic effects of the
peptide. The antimicrobial peptide’s amino acid sequence
and conformation in the monomer form will dictate its
ability to form these structures. In amphipathic peptides, the
hydrophobic domains are able to interact with the nonpolar
hydrophobic core region of the lipid bilayer thereby driving
the peptide deeper into the membrane. Alternatively they
could also interact with the hydrophobic facets of other
peptides, promoting multimerization in an attempt to avoid
exposure of these facets to the aqueous environment. This
type of multimerization and interaction with the interior
of the lipid bilayer may result in peptide lined pores or
channels being formed in the biomembrane, resulting in
loss of integrity and permeabilization. Since biomembranes
are highly variable in composition and structure, it is pos-
sible that a peptide may behave in a number of different
ways when associated with different cellular membranes [9].
Several models have been proposed to describe the pore
formation observed in membranes that have been exposed to
antimicrobial peptides.
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8.1. The Barrel-Stave Model. This mechanism of membrane
pore formation is so named because the transmembrane
peptides, or peptide complexes, lining the channel are
positioned in a barrel-like ring, with the peptides forming
transmembrane staves. Amphipathic peptides are oriented
so that the hydrophobic domains interact with the nonpolar
hydrocarbon tails located in the interior of the lipid mem-
brane, whereas the hydrophilic domains are oriented so that
they face the aqueous channel of the pore and form its lining
[24]. Initially the monomer peptides accumulate at the cell
surface and undergo conformational rearrangement when
they contact themembrane (Figure 4).This is thought to force
the phospholipid head groups aside and induce thinning
of the membrane. This allows the hydrophobic part of the
peptide to enter into the nonpolar interior of the membrane,
whilst the cationic amino acids of the antimicrobial peptide
interact with the negatively charged head groups. When the
threshold concentration of the peptides is reached the peptide
monomers are able to aggregate to form multimers which
further forces the peptides into the hydrophobic centre of
the membrane, as the aggregation prevents the hydrophilic
parts of the peptide from being exposed to the hydrophobic
parts of the innermembrane (Figure 4(a)). As ever increasing
numbers of peptide monomers aggregate, the pore in the
membrane is expanded [9, 24].
8.2.The Toroidal Pore orWorm-HoleMechanism. Thismech-
anism of pore formation has been well studied using the
𝛼-helical magainin peptides. Upon contacting the charged
cellular membrane, the disorganised peptides take on the
𝛼-helical structure. Initially the helices orientate themselves
so that they are parallel with the surface of the membrane.
The polar phospholipid head groups are displaced and the
surface of the membrane is weakened, resulting in a positive
curvature strain in the membrane. As a result of this strain
and thinning, the membrane is destabilised and becomes
more susceptible to further peptide interactions. Once a
threshold concentration of peptides is reached the peptides
reorientate so that they are perpendicular to the membrane
and begin to multimerize so that the hydrophilic parts of
the peptides are not in contact with the hydrophobic parts
of the membrane (Figure 4(b)). The newly formed toroidal
pore is unstable and upon disintegration some of the peptides
are forced into the inner leaflet of the cell membrane. It
is therefore believed that the disintegration step of these
transient pores is important as it allows the peptides to
translocate into the intracellular space, where they may act
on other targets [42].
8.3. The Carpet Model. The carpet model of membrane per-
meabilization is based on diffuse action by many monomer
peptides on the cellular membrane. When sufficiently high
concentrations of certain antimicrobial peptides are present
on the cell membrane some of the phospholipids of the
membrane are displaced which results in changes to the
membranes fluidity or brings about weaknesses in the barrier
properties of the membrane. The cumulative effect of these
displacements is that the membrane is weakened and loses
its integrity. As suggested previously, the initial attraction
of the antimicrobial peptides to the membrane is through
electrostatic attraction forces. No specific channels or pores
are formed, and it is believed that permeabilization and loss of
membrane integrity are through the unfavourable energetic
properties that dispersion of the phospholipids brings about
(Figure 4(c)) [22].
9. Impact of Bacterial Infections to Human
Health and Traditional Methods of
Infection Diagnosis
It is estimated that up to 85% of patients that are critically
ill in hospital have a fever but display no other outward sign
of infection. Since prolonged episodes of fever can be fatal,
it is essential that any underlying infection is detected as
soon as possible, so that the correct treatment regime can be
initiated [43]. Traditional methods of diagnosis may include
examination of tissue biopsies and attempting to culture
pathogens, an often inaccurate and time-consuming task
which can delay the onset of treatment. Diagnostic imaging
procedures are also employed and may include computed
tomography (CT) scanning or magnetic resonance imaging
(MRI). However, these techniques are generally not able to
detect early stage infections as they require morphological
changes in the tissues to take place, a feature usually asso-
ciated with advanced infections [44]. Furthermore, they are
generally focussed on specific parts of the body, meaning
that it is possible that the infection may be missed, or the
true extent of the infection may not be detected. Gallium-
radiolabeled antibodies or -immunoglobulins or complexes
such as 67/68Ga-citrate may be employed to highlight regions
where leukocyte trafficking is occurring using SPECT or
PET scanning. However, these technologies are unable to
definitively distinguish between infected tissues and those
that are inflamed but sterile, since leukocyte trafficking
occurs in both cases [44]. Given the high specific affinity
of naturally occurring antimicrobial peptides for pathogenic
bacteria or fungi, as opposed to cells of the host organism, it
was envisaged that theymay be employed to aid the resolution
of diagnostic imaging processes [45].
9.1. The Use of Antimicrobial Peptides as Radiopharmaceuti-
cals. Ideally, a radiopharmaceutical employed for infection
imaging should allow for rapid detection of bacteria and
rapid clearance from the noninfected sites. It should also
exhibit high and specific uptake at the infected site, with
minimal amounts accumulating in sterile or nontarget tissue.
The compound should also have low toxicity and not induce
an immune response. Very importantly, it should be able to
distinguish between a sterile and an infected inflammation
[45]. Since antimicrobial peptides generally show a broad
spectrum of activity against a wide range of pathogenic
yeasts and bacteria they are ideal targeting molecules for
infections where the suspected pathogen has not been iden-
tified. Additionally their mode of action requires them to
physically associate with the pathogen, and so they would be
able to bring a gamma or positron emitting source, such as
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(a) (b) (c)
Figure 4: Overview of possible interactionmechanism following peptide interaction with the bacterial cell membrane [53], that is, (a) barrel-
stave model (pore formation), (b) toroidal model (pore formation), and (c) carpet model (membrane disruption). Red coloured peptide
regions: hydrophilic; blue coloured peptide regions: hydrophobic.
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Figure 5: Approaches in radiolabeling of peptides. The direct method (a) where radionuclides are covalently attached to the peptide and the
indirect method (b) where radionuclides are attached to targeting peptides by means of bifunctional chelators [8].
technetium-99m (99mTc) or gallium-67 (67Ga), to the exact
location of the infection. Their lack of affinity for the host
organism’s cells alsomeans that they would not accumulate in
sterile inflamed tissues. Radiolabeled antimicrobial peptides
are also attractive because they are cleared rapidly from the
circulatory system and excreted by the body. In addition they
are also able to penetrate the extravascular tissues and thereby
accumulate at infected sites in a very short space of time [46].
Ideally, the radiolabeling procedure of a targeting molecule
should allow for the firm attachment of a radionuclide to the
molecule without it adversely affecting its targeting ability or
the pharmacokinetics of the molecule. Labelling approaches
can either be direct or indirect as follows.
(i) A direct labelling (Figure 5(a)) approach involves
incorporation of the radionuclide onto the targeting
molecule via a covalent bond. In the case of peptide
targeting molecules a covalent bond may be formed
between the radionuclide and a suitable free amide
residue of Lys andArg [47]. Using the tyrosine residue
may cause problems associated with labelling includ-
ing nonspecific or poor binding, in vivo instability of
the complex, and unwanted alterations to the peptide
structure, such as the cleaving of internal disulphide
bonds, which can alter its functioning [8].
(ii) An indirect labelling strategy can be used through
addition of chelating agents to the targeting molecule
(Figure 5(b)) [8]. Bifunctional chelates have been
used to label peptide carrier molecules with radionu-
clides. The chelating agent may be preloaded with
the radionuclide prior to being bonded to the carrier
moiety, or it could be firstly attached to the carrier
molecule and then exposed to the nuclide for chela-
tion in a process known as postlabelling. Postlabelling
has the advantage that the carrier molecule can
be stored for a long period of time until needed,
and the radionuclide, which undergoes decay, can
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Figure 6: Primary structure of ubiquicidin as originally reported by Hiemstra and coworkers [49].
Figure 7: Anterior whole-body image taken at 30min after tracer
injection showing kidneys (dotted arrow), liver (solid arrow), and
urinary bladder (ball arrow) (adapted from [52]).
be added shortly before the radiopharmaceutical is
administered. This benefits commercialisation of the
carrier molecule and makes the technology easier to
use in hospitals or clinics [48].
9.2. Ubiquicidin Exemplifies an Approach for Antimicrobial
Peptide Derived Radiopharmaceuticals. The 59-amino acid
residue antimicrobial peptide ubiquicidin (UBI) is a 6.7 kDa
peptide that was first discovered in cytosolic extracts of the
murine macrophage (Figure 6). This peptide was shown to
exhibit antimicrobial effects against Salmonella typhimurium
and Listeria monocytogenes. It was subsequently found in a
wide range of other organisms, including humans [49]. Since
it occurs naturally in man, ubiquicidin is not an immuno-
genic entity, which makes it suitable for administration as
a diagnostic tool. It also has high affinity for bacterial cells
but does not target mammalian cells, rendering it nontoxic
to the patient and selective in that it is unlikely to accumulate
at sterile inflammation sites [50]. Several studies have been
performed on fragments of ubiquicidin both in vitro and in
vivo to assess its ability to bind to bacterial cells.
Welling and coworkers [51] evaluated the whole 99mTc
labeled ubiquicidin and various radiolabeled fragments of the
peptide, including UBI1-18 (KVHGSLARAGKVRGQTPK),
UBI29-41 (TGRAKRRMQYNRR), UBI18-29 (KVAKQEKK
KKKT), UBI 18–35 (KVAKQEKKKKKTGRAKRR), UBI31-
38 (RAKRRMQY), and UBI22-35 (QEKKKKKTGRAKRR)
for their ability to bind to bacterial cells and/or human
leukocytes in vitro. They found that the ubiquicidin peptide
fragments UBI 18–35, UBI 31–38, UBI 22–35, and UBI 29–
41 showed considerably higher binding affinities for the
bacterial cells than they did for the human leukocytes. The
in vivo results, obtained by scintigraphy of experimentally
infected mice following intravenous administration of the
various radiolabeled peptides showed that the UBI18-35
and UBI29-41 peptides appeared to be the most promising
candidates. After a postadministration period of 2 h and 24 h,
the leukocyte to bacteria binding ratios were 1 : 36, 1 : 166,
and 1 : 73, 1 : 220 for UBI18-35 andUBI29-41, respectively.The
researchers concluded that UBI29-41 and UBI18-35 were the
optimal peptides for distinguishing infections from sterile
inflammations.
9.3. Human Clinical Trials of 99mTc-Ubiquicidin 29–41 as an
Infection Imaging Agent. Akhtar and coworkers [52] studied
the efficacy of 99mTc-UBI 29–41 as an infection imaging agent
in eighteen patients with suspected prosthetic or soft tissue
infections. Using scintigraphy to monitor the radiolabeled
peptide, the researchers were able to monitor the target to
nontarget (T/NT) ratios of the imaging agent. Infection in the
patients was confirmed through culture of bacteria from the
infected site, or where this was not possible through complete
blood examination.The study found that all patients tolerated
the radiolabeled peptide well, no significant changes to their
vital signs were noted, and no related side effects were seen
following the administration of the 99mTc-UBI 29–41. The
T/NT ratio was determined at 30, 60, and 120 minutes, with
the 30-minute scan showing the highest mean T/NT value.
The anterior whole-body scan (Figure 7) gave information
about the biodistribution of the tracer and its routes of
elimination by the body. It can be seen that the tracer ismostly
eliminated by the urinary system and also some perfusion-
dependant liver activity was noted. The imaging agent was
found to have a sensitivity of 100% and a specificity of 80%.
The researchers concluded that the 99mTc-UBI 29–41 had
a positive predictive value of 92.9%, a negative predictive
value of 100%, and an overall diagnostic accuracy of 94.4%.
The radiolabeled peptide displayed efficacy against a range
of different bacteria, including Pseudomonas aeruginosa,
Staphylococcus aureus, and Streptococcus pyogenes. It was the
opinion of the researchers that 99mTc-UBI 29–41 is a highly
sensitive and specific imaging agent for detecting soft tissue
and bone infections in humans.
10. Discussion and Perspective
The usage of nuclear medicine modalities such as SPECT
or PET allows clinicians for noninvasive whole-body exam-
ination of physiological processes such as occult infection
at cellular level and, apart from being a useful tool for
physiological and medical research, these highly sensitive
technologies are capable of detection of diseases without, or
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prior to, anatomical change (fever of unknown origin). To
date, radiolabeled leukocytes, monoclonal antibodies against
cytokines/leukocytes, and tracers associated with specific
molecular targets or metabolic processes are utilized [54].
Radiolabeled leukocytes have a spectrum of limitations
(alteration of leukocyte function due to radiation damage),
that is, they have a cumbersome pharmakokinetic and are
also relatively nonspecific. Moreover, labeled leukocytes and
high molecular weight tracers such as antibodies may also
have limited penetration into infected or diseased tissues.
The latter presented overview which clarifies the widespread
potential of AMPs to be evaluated as imaging probes, given
their unique selective involvement with bacteria. A sim-
ple literature query, searching for “antimicrobial peptides”
resulted in ca. 6000 publications. However, as soon as the
query is combined with the term “imaging”, it resulted in
only 63 publications; only 17 of those have clinical relevance
(99mTc-UBI-29-41 related studies/trials).This is an important
observation as this ubiquicidin fragment may represents
a near-perfect carrier for targeting molecules for infection
detection. The human clinical trials conducted by Akhtar
and coworkers [52] with 99mTc-UBI 29–41 did not find any
evidence of cytotoxicity in the patients which supports the
findings of the current study. Even though it was stated
that the signal to noise ratio is low [46], it has been used
successfully for 10 years now. In 2010 the clinical trials
to date were justified by de Murphy et al. towards their
diagnostic value over the initial 7-year period. 99mTc-UBI 29–
41 meta-analysis returned high values for sensitivity (96.3%),
specificity (94.1%), and accuracy (95.3%) with high positive
predictive (95.1%) and negative predictive values (95.5%)
[54]. From 2011 onwards, seven additional clinical studies
(enrolling together over 160 patients) have been successfully
carried out and all demonstrated 99mTc-UBI29-41-SPECT
as a highly accurate and selective diagnostic tool for bone
infection in diabetic foot [55], hip prostheses [56], or other
implant related infections [57, 58]; moreover it also detects
osteomyelitis [59, 60] and infective endocarditis [61]. It
can be ascertained that this field of applications for 99mTc-
UBI29-41 imaging will keep growing also because research
with alternative radioisotopes other than 99mTc may yield
a new group of radiopharmaceutical agents for medical
diagnostic imaging using clinical PET/CT or PET/MRI in
future. Novel radioisotopes such as 68Ga, 82Rb, or 62Cu
can be produced on-demand from a radioisotope generator
without the need for an on-site cyclotron and may serve
as radionuclides for PET. 68Ga has garnered interest as a
positron emitter for molecular imaging due to some of the
advantages it offers in a tracer. It has a radioactive half-life
of 67.71 minutes which makes it compatible with biokinetics
of most low molecular weight radiopharmaceuticals such as
peptides, oligonucleotides, aptamers, or antibody fragments.
The nuclear decay of the isotope is mainly through positron
emission (89%), with average positron energy of 740 keV.
Additionally, the coordination chemistry of Ga3+ is well
understood, which is helpful in designing chelating agents
which can be used to link this radionuclide to a targeting
vector [62]. Recently, UBI29-41 was conjugated to themacro-
cycle 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)
and subsequently labeled with 68Ga [63]. This approach
was initially utilized with 1,4,7,10-tetraazacyclododecane-
N󸀠,N󸀠󸀠,N󸀠󸀠󸀠,N󸀠󸀠󸀠󸀠-tetraacetic acid (DOTA) to yield the peptide
derivatives such as DOTA-TOC or DOTA-TATE for 68Ga-
complexation which subsequently allowed tumor-receptor-
based PET imaging. In a preclinical study using 68Ga-
NOTAUBI29-41-PET it was shown that the macrocycle
conjugation did not compromise the peptide’s ability to
selectively bind to bacteria in vivo [64]. Aside from UBI,
there are other compounds evaluated for infection and
inflammation imaging [54] but the majority of antimicro-
bial peptides available remain underinvestigated in terms
of infection imaging. In 2000 the human neutrophil pep-
tides (HNP1-3) were considered amongst other peptides as
useful agent for targeting infection, as part of the defence
mechanism in monocyte/lymphocyte cultures HNPs plays
a chemotactic role as mediating molecules. This ambiguous
role may be a drawback in developing HNPs for imaging;
hence the usage of particular peptides as targeting vec-
tors may have some secondary limitations, despite of their
favourable cellular properties [65]. As radiopharmaceuticals
are mostly administered by i.v. injection, the peptides can
be prone to enzymatic degradation or the destabilisation
of the radioisotope as reported for 18F-UBI29-41 [66]. The
lactoferrin-derived peptide hLF(1-11) showed great sensitivity
as infection agent targetingmultidrug-resistantAcinetobacter
baumannii strains; however binding to Candida albicans, a
fungus, and the hepatobiliar excretionmade it less favourable
for imaging [51]. Moreover hLF showed immune-activating
or bactericidal effects depending on the dose administered,
that is, encountered with a negative feedback mechanism by
interleukin-10 modulation [67, 68]. Another example, the
AMP Latarcin-2a, extracted from the venom of the Central
Asian spider Lachesana tarabaevi, has undesirable lytic activ-
ity against Gram-positive and Gram-negative bacteria, ery-
throcytes, and yeast at micromolar concentrations and thus
makes it less considered for bacterial detectionwith PET [69].
Moreover, most bacteria are able to produce both, surface-
bound and/or secretory proteases, a defence strategy that
can degrade or inactivate AMPs. Consequently, using AMP-
derived compounds as imaging agents would result in false-
negative diagnostics where a persistent infectionmight easily
be misjudged or overseen entirely. Through understanding
these specific bacteria-intrinsic defence mechanisms, it can
be avoided to use vulnerable AMP-derived structures as
infection imaging agents. It should also be noted that, except
for a few structures, research did not reveal a bacteria-
specific receptor-like target that complements the potential
peptides as a ligands or allosteric modulators. Tumor cells,
in contrast, express specific receptors integrin-, bombesin-,
or somatostatin ligands or antagonists which are targeted
by SPECT or PET tracers [10, 70]. Moreover, the host’s
immune system, when reacting on infections, has patho-
logic pathways that can be imaged using PET. Activated
macrophages may act as an equivalent host-dependent target
which can be visualized by 18F-FDG nonspecifically [3] but
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the actual bacterial burden remains overseen. In contrast,
AMP-derived peptides are acting in a host-independent
mechanism: radiolabeled peptides will bind to free and
to cell-adherent but not phagocytised bacteria and hence
bacteria become invisible for 99mTc-UBI29–41-SPECT once
they are incorporated by macrophages [71]. The use of this
modality potentially allows for the early detection of infection
prior to any morphological changes in the body taking place
[7]. It also allows for the discrimination of infection from a
sterile inflammation which may appear superficially similar
as both may present as reddened, swollen, and unusually
warm areas.This is due to the increased blood flow, enhanced
vascular permeability, and influx of white blood cells which
are common in both situations [4].The latter approachwould
emphasize a dual tracer imaging regimen in future clinical
studies or even dual tracer administration (if the respective
radioisotope properties and pharmacokinetic properties are
complementing the approach). In summary, the ideal tracer
for clinical PET imaging of infection should meet several
criteria. (1) It should sustain substantial blood degradation
and have a reasonable degree of lipophilicity; (2) it should
accumulate and be retained at the site of infection (ideally by
internalization and subsequent amplification), with minimal
accumulation in noninfected sites; (3) it should have rapid
clearance of nonspecific activity uptake from the surrounding
regions for high signal-to-noise-ratios; and (4) it should
have minimal side effects and should be easy to prepare,
at low cost. UBI29-41 has proven its usefulness towards
generic infection imaging, and other suitable AMPs based
radiopharmaceuticals will follow, undoubtedly.
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